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V
ery few studies have focused on the involvement
of protein kinase C (PKC) in mediating -cell
dysfunction, which is surprising because there
are several hundred articles addressing a corre-
sponding role for PKC during insulin resistance. The
conventional and novel subgroups of this family of serine-
threonine, protein kinases are usually activated in recep-
tor signaling cascades by lipid second messengers. Under
conditions of lipid oversupply, however, it was envisioned
that nutrient fatty acids or their derivatives might also
activate PKC and thereby disrupt both insulin signaling
and, more speculatively, -cell function (1). Important
support for this concept in -cells is now provided in this
issue of Diabetes (2).
Hennige et al. (2) generated transgenic mice that over-
express a catalytically inactive form of PKC speciﬁcally
in -cells. This competes functionally with endogenous
PKC and inhibits its activity in a relatively speciﬁc
manner. This strategy improved the glucose intolerance
caused by feeding mice a high-fat diet; minimal effects
were seen in normal chow–fed mice. The improvement
was accompanied in vivo by an enhancement of glucose-
stimulated insulin secretion, an increase in mean islet size,
and a reduction in markers of apoptosis. This is consistent
with a generally proapoptotic role of PKC reported in a
few prior investigations of -cells (3–5) and studied more
extensively in several other cell types (6). The current
study also demonstrates that once the alteration in -cell
mass is taken into account, PKC does not appear to
regulate insulin secretion directly.
Translocation of PKC from the cytosol to the nucleus
often accompanies apoptosis (6) and, indeed, correlates
with the capacity of different fatty acids to promote -cell
death (5). The study by Hennige et al. now shows that
nuclear localization of the transcription factor FOXO1 is
stimulated in vitro by a saturated proapoptotic fatty acid
(palmitate) and that this depends on PKC activation.
Moreover, phosphorylation of FOXO1 on Ser256, a key
event for nuclear exclusion, is inhibited by overexpression
of wild-type PKC and augmented by the catalytically
inactive mutant. Although it remains to be conﬁrmed
whether the observed regulation of apoptosis by PKC is
causally mediated by changes in FOXO1 localization, this
observation is consistent with some prior work. FOXO1
phosphorylation and apoptosis are inversely regulated in
-cells chronically exposed to fatty acids, and both fea-
tures can be counteracted by the growth factor IGF in a
manner dependent on the antiapoptotic protein kinase akt
(7). In a further twist, fatty acids can inhibit akt, and this
contributes permissively to their apoptotic potential (8).
Activation of PKC has been previously implicated in this
inhibition of akt (9), so it will now be important to
determine whether this involves PKC speciﬁcally (Fig. 1).
Other questions remain to be resolved. In particular
there is extensive evidence implicating endoplasmic retic-
ulum (ER) stress in -cell lipoapoptosis (10,11). Although
not addressed directly, Hennige et al. suggest that PKC
might link ER stress with mitochondrial apoptosis as
hypothesized for other cell types (12). Alternatively, PKC
could act upstream of ER stress, perhaps via inhibition of
autophagy (13). Another possibility is that ER stress and
PKC represent separate pathways, used differentially
depending on the duration and especially extent of fatty
acid exposure (Fig. 1). Although not always appreciated,
the free fatty acid concentration is determined by the ratio
of fatty acid to albumin, and this varies widely among
various studies. Under moderate exposure (fatty acid–to–
albumin ratio 4) ER stress was shown to be responsible
for the majority of -cell apoptosis (11). At the higher ratio
used by Hennige et al. (10) it is possible that other
mechanisms, perhaps including PKC and/or FOXO1,
come into play. Interestingly, one of the genes regulated by
FOXO1 is the transcription factor C/EBP homologous
protein (CHOP) (14). This is a major mediator of -cell
death due to ER stress during moderate lipid exposure
(15,16), but CHOP is also induced independently of ER
stress. Thus, PKC and FOXO1 could contribute to CHOP-
mediated apoptosis in a manner that becomes quantita-
tively more important at fatty acid concentrations higher
than those required for ER stress. Conversely, use of lower
effective concentrations of fatty acids might explain a
previous report that PKC was not involved in -cell
apoptosis (17).
Whatever the mechanisms, it is now clear that inhibiting
PKC speciﬁcally in -cells does improve both -cell
function and glucose tolerance in mice maintained on a
high-fat diet (2). This raises the potential of inhibiting of
PKC to treat type 2 diabetes. This possibility is under-
scored by a recent study using whole-body deletion of
PKC in which glucose intolerance due to high-fat feeding
was also reduced (18). In this instance the major mecha-
nism appeared to be an improvement in hepatic lipid
metabolism and insulin sensitivity. Perhaps a -cell phe-
notype would have been more apparent if, as with Hennige
et al., a diet enriched in saturated (as opposed to polyun-
saturated) fatty acids had been used (18). In any event,
these two studies now suggest that inhibition of PKC
might exert beneﬁts at multiple sites. This would be
analogous to a proposed rationale for inhibiting PKCε ,
which has been broadly implicated as negative regulator of
insulin sensitivity (1). However, inhibition of PKCε also
results in a pronounced enhancement of glucose-stimu-
From the
1Garvan Institute of Medical Research, Sydney, Australia; and
2St.
Vincent’s Clinical School, Faculty of Medicine, University of New South
Wales, Sydney, Australia.
Corresponding author: Trevor J. Biden, t.biden@garvan.org.au.
DOI: 10.2337/db09-1439
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying original article, p. 119.
COMMENTARY
diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 1lated insulin secretion, speciﬁcally from defective or lipid-
pretreated -cells (19). This, together with an independent
phenotype involving diminished hepatic clearance of insu-
lin, greatly enhances insulin availability and accounts for
most of the observed improvement of glucose tolerance, at
least in long-term models of high-fat feeding. Unlike the
situation with PKC, inhibition of PKCε did not augment
-cell mass (19) but speciﬁcally upregulated the ampliﬁ-
cation pathway for glucose-stimulated insulin secretion
(20). The complementarity in function of these two PKC
isoforms, and the difﬁculties associated with developing
truly selective inhibitors, suggests that a single molecule
antagonising both PKC and PKCε might constitute a
suitable therapy for type 2 diabetes. At the very least, a
better understanding of the roles of these key PKC iso-
forms, their substrates, and manners of activation should
shed much-needed light on the molecular mechanisms
underpinning type 2 diabetes.
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FIG. 1. Potential sites of action of PKC in regulating -cell apoptosis due to chronic exposure to saturated fatty acids. Pathways that are well
established, including those now arising from the study by Hennige et al., are shown with solid lines. More speculative links concerning how PKC
might impact other pathways that regulate -cell mass, including ER stress and akt signaling, are shown as dashed lines. As outlined in this article,
it is possible some of these individual pathways might play greater or lesser roles depending on the duration and extent of fatty acid exposure.
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